Real-life use of oral disease-modifying treatments in Austria.
Michael GugerChristian EnzingerFritz LeutmezerJörg KrausStefan KalcherErich KvasThomas Bergernull nullPublished in: Acta neurologica Scandinavica (2019)
In the AMSTR, there was no difference concerning ARR, probability for a relapse, EDSS change, treatment interruption, EDSS progression or regression between oral DMTs, except regarding less sustained EDSS progression for 12 weeks concerning DMF vs fingolimod.